Breast cancer and Flammer syndrome: Any symptoms in common for prediction, prevention and personalised medical approach?

EPMA Journal

Volumn 8, Issue 2, 2017, Pages 129-140

  Zubor, Pavol ^a,b   Gondova, Alexandra ^a   Polivka, Jiri ^c,d   Kasajova, Petra ^a   Konieczka, Katarzyna ^e   Danko, Jan ^a   Golubnitschaja, Olga ^f  

^a Martinska Fakultna Nemocnica   (Slovakia)

^b University Hospital in Martin   (Slovakia)

^c CHARLES UNIVERSITY   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

^e UNIVERSITY OF BASEL   (Switzerland)

^f UNIVERSITY OF BONN   (Germany)

Author keywords

Breast cancer; Cardiovascular component; Drug sensitivity; Flammer syndrome; Pain; Patient stratification; Predictive preventive personalised medicine; Sense regulation; Systemic hypoxia; Thermoregulation

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COLD SENSATION; CONTROLLED STUDY; DEHYDRATION; DISEASE PREDISPOSITION; DIZZINESS; DRUG SENSITIVITY; FEMALE; FLAMMER SYNDROME; HEADACHE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MIGRAINE; PERSONALIZED MEDICINE; PILOT STUDY; PREDICTION; PREVENTION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; SENSORY DYSFUNCTION; SLEEP DISORDER; SYMPTOM; SYNDROME; THERMOREGULATION; VASCULAR DISEASE;

EID: 85020744478     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1007/s13167-017-0089-3     Document Type: Article

References (30)

1. Golubnitschaja O, Debald M, Yeghiazaryan K, Kuhn W, Pešta M, Costigliola V, Grech G. Breast cancer epidemic in the early 21st century: evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures. Tumor Biol. 2016;37(10):12941-57. doi: 10.1007/s13277-016-5168-x.
2. Golubnitschaja O. Feeling cold and other underestimated symptoms in breast cancer: anecdotes or individual profiles for advanced patient stratification? EPMA J. 2017;8(1):17-22. doi: 10.1007/s13167-017-0086-6.
3. Konieczka K, Ritch R, Traverso CE, Kim DM, Kook MS, Gallino A, et al. Flammer syndrome. EPMA J. 2014;5(1):11. doi: 10.1186/1878-5085-5-11.
4. Yeghiazaryan K, Flammer J, Orgül S, Wunderlich K, Golubnitschaja O. Vasospastic individuals demonstrate significant similarity to glaucoma patients as revealed by gene expression profiling in circulating leukocytes. Mol Vis. 2009;15:2339-48.
5. Flammer J, Konieczka K, Flammer AJ. The primary vascular dysregulation syndrome: implications for eye diseases. EPMA J. 2013;4(1):14. doi: 10.1186/1878-5085-4-14.
6. Yeghiazaryan K, Flammer J, Golubnitschaja O. Predictive molecular profiling in blood of healthy vasospastic individuals: clue to targeted prevention as personalised medicine to effective costs. EPMA J. 2010;1(2):263-72. doi: 10.1007/s13167-010-0032-3.
7. Golubnitschaja O, Yeghiazaryan K, Flammer J. Key molecular pathways affected by glaucoma pathology: is predictive diagnosis possible? EPMA J. 2010;1(2):237-44. doi: 10.1007/s13167-010-0031-4.
8. Golubnitschaja O, Yeghiazaryan K, Costigliola V, Trog D, Braun M, Debald M, et al. Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? EPMA J. 2013;4(1):6. doi: 10.1186/1878-5085-4-6.
9. Flammer J, Konieczka K. Retinal venous pressure: the role of endothelin. EPMA J. 2015;6:21. doi: 10.1186/s13167-015-0043-1.
10. Fang L, Baertschi M, Mozaffarieh M. The effect of flammer-syndrome on retinal venous pressure. BMC Ophthalmol. 2014;14:121. doi: 10.1186/1471-2415-14-121.
11. Fraenkl SA, Mozaffarieh M, Flammer J. Retinal vein occlusions: the potential impact of a dysregulation of the retinal veins. EPMA J. 2010;1(2):253-61. doi: 10.1007/s13167-010-0025-2.
12. Konieczka K, Flammer AJ, Todorova M, Meyer P, Flammer J. Retinitis pigmentosa and ocular blood flow. EPMA J. 2012;3(1):17. doi: 10.1186/1878-5085-3-17.
13. Konieczka K, Koch S, Binggeli T, Schoetzau A, Kesselring J. Multiple sclerosis and primary vascular dysregulation (Flammer syndrome). EPMA J. 2016;7:13. doi: 10.1186/s13167-016-0062-6.
14. Konieczka K, Fränkl S. Primäre vaskuläre dysregulation und Glaukom (primary vascular dysregulation and glaucoma). Z Prakt Augenheilkd. 2013;34:207-15.
15. Konieczka K. Flammer syndrome, in: Brähler E, Hoefert H-W. Lexikon der Modernen Krankheiten. 2014, Medizinisch Wissenschaftliche Verlagsgesellschaft. Berlin. Deutschland.
16. Konieczka K, Choi HJ, Koch S, Schoetzau A, Küenzi D, Kim DM. Frequency of symptoms and signs of primary vascular dysregulation in Swiss and Korean populations. Klin Monatsbl Augenheilkd. 2014;231:344-7.
17. Konieczka K, Koch S, Schoetzau A, Todorova MG. Increased prevalence of Flammer syndrome in patients with retinitis pigmentosa. Klin Monatsbl Augenheilkd. 2016;233(4):448-52. doi: 10.1055/s-0041-111802.
18. Konieczka K, Todorova MG, Chackathayil TN, Henrich PB. Cilioretinal artery occlusion in a young patient with Flammer syndrome and increased retinal venous pressure. Klin Monatsbl Augenheilkd. 2015;232:576-8. doi: 10.1055/s-0035-1545774.
19. Konieczka K, Flammer J, Sternbuch J, Binggeli T, Fraenkl S. Leber's hereditary optic neuropathy, normal tension glaucoma, and Flammer syndrome: long term follow-up of a patient. Klin Monatsbl Augenheilkd. 2017; doi: 10.1055/s-0042-119564.
20. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. WHO classification of tumours of the breast. 4th ed. Lyon: IARC; 2012.
21. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403-10.
22. Edge SB, Compton CC. The American joint committee on cancer: the American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471-4. doi: 10.1245/s10434-010-0985-4.
23. Hammond MEH, Haves DF, Wolff AC, Mangu PB, Temin S. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134:E1-E16.
24. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Hayes DF, et al. American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997-4013. doi: 10.1200/JCO.2013.50.9984.
25. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138(2):241-56. doi: 10.5858/arpa.2013-0953-SA.
26. Golubnitschaja O, Flammer J. What are the biomarkers in glaucoma? Surv Ophthalmol. 2007;52(Suppl 2):S155-61. doi: 10.1016/j.survophthal.2007.08.011.
27. Kokolus K, Hing CC, Repasky EA. Feeling too hot or cold after breast cancer: is it just a nuisance or a potentially important prognostic factor? Int J Hyperth. 2010;26(7):662-80. doi: 10.3109/02656736.2010.507235.
28. Mencalha A, Victorino VJ, Cecchini R, Panis C. Mapping oxidative changes in breast cancer: understanding the basic to reach the clinics. Anticancer Res. 2014;34(3):1127-40.
29. Liu X, Feng D, Liu D, Wang S, Yu X, Dai E, Wang J, Wang L, Jiang W. Dissecting the origin of breast cancer subtype stem cell and the potential mechanism of malignant transformation. PLoS One. 2016;11(10):e0165001. doi: 10.1371/journal.pone.0165001.
30. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer. 2001;92(S6):1684-8.